NCT00439179 (BrUOG-PA205) is a Phase 1 clinical trial of cohort 1 in Metastatic Pancreatic Cancer, sponsored by Brown University.

Who is sponsoring NCT00439179?

NCT00439179 is sponsored by Brown University.

What drugs are being tested in NCT00439179?

Interventions in NCT00439179: cohort 1, cohort 2, cohort 3, cohort 4.

What condition does NCT00439179 study?

NCT00439179 studies Metastatic Pancreatic Cancer.

Is NCT00439179 still recruiting?

NCT00439179 is currently completed. Last updated 13 February 2020.

Are results published for NCT00439179?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-02-13 · How we verify

NCT00439179: BrUOG-PA205

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BrUOG-PA-205 A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema GSK Study ProtocolGSK #103556

Completed Phase 1 Results posted Last updated 13 February 2020

What this trial tests

Phase 1 trial testing cohort 1 in Metastatic Pancreatic Cancer in 27 participants. Completed in 1 December 2007.

Timeline

1 July 2006

Primary endpoint
1 December 2007

1 December 2007

Quick facts

Lead sponsor	Brown University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	1 July 2006
Primary completion	1 December 2007
Estimated completion	1 December 2007
Sites	1 location across United States

Drugs / interventions tested

cohort 1
cohort 2
cohort 3
cohort 4

Conditions studied

Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →

Sponsor

Brown University

Who can join

18 and older, any sex, with Metastatic Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Toxicity (Number of Patients Who Experiened DLTs)
Time frame: until death, approximately 2 years
To determine the safety and tolerability of GW572016 when administered with gemcitabine and the combination of gemcitabine and oxaliplatin in patients with advanced pancreaticobiliary cancers. Numbers below are DLTs

Sponsor's own description

A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Metastatic Pancreatic Cancer

Currently open trials in the same condition.

NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
NCT06951997 — QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer · Phase 2 · recruiting
NCT06533332 — A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors · Phase 1 · recruiting

Other Brown University trials

Trials by the same sponsor.

NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g · Phase 2 · not yet recruiting
NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption · Phase 2 · recruiting
NCT07398443 — Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults · NA · recruiting
NCT05901766 — Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment · Phase 4 · not yet recruiting
NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00439179 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brown University
Last refreshed: 13 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00439179.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing